

New Frontiers in Intestinal Failure: The Latest and Greatest

~ LIVE WEBINAR ~

WEDNESDAY, MAY 8, 2019 - 8:00PM ET

Please join [NASPGHAN](#) and the [NASPGHAN Foundation](#) for a 60-minute webinar on **the latest developments in intestinal failure**. CME, MOC Part II and CPE credits will be available.

CHAIR

Valeria Cohran, MD
Medical Director, Intestinal Rehabilitation and Transplantation
Attending Physician, Gastroenterology
Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine



FACULTY

Alexandra Carey, MD
Director, Home Parenteral Nutrition Program; Attending Physician, Division of
Gastroenterology, Hepatology and Nutrition
Instructor of Pediatrics, Harvard Medical School




FACULTY

Samuel Kocoshis, MD
Professor of Pediatrics, University of Cincinnati College of Medicine
Medical Director, Intestinal Care Center and Intestinal Transplantation
Cincinnati Children's Hospital Medical Center



FACULTY

Robert S. Venick, MD
Associate Professor of Pediatrics and Surgery
Division of Pediatric GI, Hepatology and Nutrition
David Geffen School of Medicine, UCLA
Director of Pediatric Liver and Intestinal Transplant Services
Mattel Children's Hospital UCLA



CME REVIEWER

Jennifer A. Strople, MD
Attending Physician, Gastroenterology, Hepatology and Nutrition

Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine
Ann & Robert H. Lurie Children's Hospital of Chicago

INTRODUCTION

The area of Intestinal Rehabilitation has changed significantly over the past 10-15 years. New innovations such as alternative lipids and the development of Intestinal Rehabilitation programs have drastically improved the survival of patients with short bowel syndrome and intestinal failure. The purpose of this webinar is to review the current state of Intestinal Rehabilitation and the new frontier of changes, including the use of agents such as Teduglutide to enhance intestinal adaptation.

Dr. Samuel Kocoshis is nationally known and recognized for his expertise in intestinal rehabilitation and transplant. He will review the current status of Intestinal Transplantation in this era of Intestinal Rehabilitation. Dr. Alexandra Carey will discuss the practical management in the utilization of alternative lipids. Dr. Robert Venick has expertise with the use of Teduglutide in adult patients, and with his role as a PI in the pediatric studies, will discuss his experience in this exciting new frontier. Dr. Valeria Cohran will serve as the moderator. The ultimate goal of the webinar is to enhance the knowledge of the practicing pediatric gastroenterologists in this rapidly changing and expanding field.

TARGET AUDIENCE

This activity is designed for pediatric gastroenterologists, pediatric gastroenterology fellows, pediatric gastroenterology nurse practitioners and pediatric gastroenterology dietitians.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Define Intestinal Failure Associated Liver Disease (IFALD)
- Understand what the current state of knowledge is regarding the pathophysiology of IFALD.
- Describe the two alternative lipid preparations utilized in intestinal failure patients in North America.
- Review the potential adverse effects of using alternative lipids.
- Understand the mechanism of how GLP-2 works and what is the evidence for its use in adult patients.
- Review the pediatric study using GLP-2 in children with intestinal failure.
- Describe the current status of intestinal transplant in the era of intestinal rehabilitation given the usage of alternative lipids and other newer innovations.

SATISFACTORY COMPLETION

Learners must complete an evaluation form to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and The NASPGHAN Foundation for Children's Digestive Health and Nutrition. NASPGHAN is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

NASPGHAN designates this enduring activity for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.



ABP MOC PART 2 CREDITS

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 1.0 MOC Part 2 points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit. Participant must complete the assessment within 30 days of the activity. Participant information will be uploaded to ABP 30 days post activity.

DIETITIANS

NASPGHAN is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program.

STATEMENT OF DISCLOSURE:

Alexandra Carey, MD reports that in the past 12 months, she has had the following relevant relationships with the manufacturer of SMOFlipid® and Omegaven®:

- PI in a phase 1 study
- Study drug (Omegaven®) provided by Fresenius Kabi

Samuel Kocoshis, MD reports he is a member of the Abbott Nutrition Speakers' Bureau and he has received grant support from Shire-Takeda Pharmaceuticals.

Robert Venick, MD reports that in the past 12 months, he has served as a site PI for pediatric Teduglutide trials (Gattex® NPS, Shire, Takeda Pharmaceuticals), and that he has had no other relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this CME activity. He states that he does not intend to discuss an unapproved or investigative use of a commercial product or device in my presentation.

Valeria Cohran, MD reports she has nothing to disclose.

Jennifer Strople, MD reports she has nothing to disclose.

Planners Monique Taylor and Kathleen Regan report that they have nothing to disclose.

In accordance with ACCME Standards for Commercial Support of CME, NASPGHAN and The NASPGHAN Foundation implemented mechanisms to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity. To resolve identified conflicts of interest, the educational content was peer-reviewed by a physician member of the NASPGHAN Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

MEDIUM OR COMBINATION OF MEDIA USED

This activity consists of a slide set plus online posttest and CME evaluation.

HOW TO RECEIVE CME CREDIT

To receive CME credit for this activity, participants must pass the posttest and complete evaluation questions at <http://naspghan.cmecertificateonline.com> and select "New Frontiers in Intestinal Failure". Certificates will be provided immediately after completion of both the posttest and evaluation. For any questions about receiving credit, please e-mail Tracy Sandstrom at tracy@amedcoemail.com.

PROVIDER INFORMATION

Jointly sponsored by NASPGHAN and The NASPGHAN Foundation. For questions, please contact:

NASPGHAN Foundation
Monique Taylor
714 Bethlehem Pike, Ambler, PA 19002-2655
Phone: (215) 641-9800 Fax: (215) 641-1995

DISCLAIMER

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of NASPGHAN, The NASPGHAN Foundation, or Shire. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

POLICY ON PRIVACY AND CONFIDENTIALITY

NASPGHAN and The NASPGHAN Foundation will make every effort to protect the privacy of every individual participant of this activity and will use information gathered only to maintain records as required by the American Medical Association (AMA) and ACCME.

This activity does not require readers to register to review the material, with the exception of physicians and other health care providers who desire to receive CME credit for this accredited activity. If an individual completes a CME for this accredited activity, we are required by the AMA and ACCME to collect personal information on the individual, such as their name, address, and phone number, that will allow us to issue a CME certificate to them and to keep this information on file for up to 6 years. Personal information gathered will not be released to any other company or organization for any purpose. This information remains totally confidential.

COMPUTER REQUIREMENTS

PC or Mac, a high-speed Internet connection and speakers required.

The webinar begins May 8, 2019 at 8:00pm ET. No content will be available prior to that time.

Jointly sponsored by NASPGHAN and The NASPGHAN Foundation.

This educational activity is supported by an independent medical education grant from Takeda.

© Copyright 2019 NASPGHAN and The NASPGHAN Foundation

Produced by [Limelight Communications](#)